| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, DC 20007; St. Louis University School of Medicine, St. Louis, Missouri 63104; and the Holland Research Labs, American Red Cross, Rockville, Maryland 20850
The insulin-like growth factors IGF-I and IGF-II are potent mitogens for several breast tumor cell lines in culture. Additionally, both IGF-I and IGF-II mRNAs are easily detected in the majority of breast tumor specimens examined, while no breast cancer epithelial cell lines we have studied express authentic IGF-I mRNA, and few lines express IGF-II mRNA. Although receptors for insulin, IGF-I, and IGF-II have been described, there is significant cross-reactivity between the various receptors and ligands in the insulin/insulin-like growth factor family, and it is not clear which receptor or receptors are responsible for the biological effects of these growth factors in this system.
Using an RNase protection assay, we examined breast tumor specimens and breast cancer epithelial cell lines for expression of mRNA encoding the type I and type II IGF receptors as well as the insulin receptor. Virtually all of the specimens examined expressed mRNA for all three receptors. We then examined estrogen-dependent MCF-7 cells for the mitogenic effects of IGF-I and II in the presence of antibodies to both the type I and type II receptors. 
IR-3, a monoclonal antibody which blocks the type I receptor, abolished the mitogenic effects of both IGF-I and IGF-II. It did not, however, block the mitogenic effects of insulin. We conclude that type I and type II IGF receptors are ubiquitously expressed in breast cancer, and our experiments with MCF-7 cells suggest the mitogenic effects of both IGF-I and IGF-II are mediated via the type I IGF receptor.
1 Supported in part by a grant from the Ladies Auxiliary to the Veterans of Foreign Wars.
Received 6/29/89. Revised 9/27/89. Accepted 10/ 3/89.
This article has been cited by other articles:
|
|
 |
|
  G. C. Kabat, M. Kim, R. T. Chlebowski, J. Khandekar, M. G. Ko, A. McTiernan, M. L. Neuhouser, D. R. Parker, J. M. Shikany, M. L. Stefanick, et al. A Longitudinal Study of the Metabolic Syndrome and Risk of Postmenopausal Breast Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2009; 18(7): 2046 - 2053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Gunter, D. R. Hoover, H. Yu, S. Wassertheil-Smoller, T. E. Rohan, J. E. Manson, J. Li, G. Y. F. Ho, X. Xue, G. L. Anderson, et al. Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women J Natl Cancer Inst, January 7, 2009; 101(1): 48 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Wang, F.-B. Wang, Q.-G. Zhang, Z.-Z. Shen, and Z.-M. Shao Enhanced Expression of Rab27A Gene by Breast Cancer Cells Promoting Invasiveness and the Metastasis Potential by Secretion of Insulin-Like Growth Factor-II Mol. Cancer Res., March 1, 2008; 6(3): 372 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Rowinsky, H. Youssoufian, J. R. Tonra, P. Solomon, D. Burtrum, and D. L. Ludwig IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Clin. Cancer Res., September 15, 2007; 13(18): 5549s - 5555s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Turturro, G. Von Burton, and E. Friday Hyperglycemia-Induced Thioredoxin-Interacting Protein Expression Differs in Breast Cancer-Derived Cells and Regulates Paclitaxel IC50 Clin. Cancer Res., June 15, 2007; 13(12): 3724 - 3730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Allen, C. Saba, E. A. Armstrong, S.-M. Huang, S. Benavente, D. L. Ludwig, D. J. Hicklin, and P. M. Harari Insulin-like Growth Factor-I Receptor Signaling Blockade Combined with Radiation Cancer Res., February 1, 2007; 67(3): 1155 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wang, G. Chakravarty, S. Kim, Y. D. Yazici, M. N. Younes, S. A. Jasser, A. A. Santillan, C. D. Bucana, A. K. El-Naggar, and J. N. Myers Growth-Inhibitory Effects of Human Anti-Insulin-Like Growth Factor-I Receptor Antibody (A12) in an Orthotopic Nude Mouse Model of Anaplastic Thyroid Carcinoma Clin. Cancer Res., August 1, 2006; 12(15): 4755 - 4765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hopfner, V. Baradari, A. Huether, C. Schofl, and H. Scherubl The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr. Relat. Cancer, March 1, 2006; 13(1): 135 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Knowlden, I. R. Hutcheson, D. Barrow, J. M. W. Gee, and R. I. Nicholson Insulin-Like Growth Factor-I Receptor Signaling in Tamoxifen-Resistant Breast Cancer: A Supporting Role to the Epidermal Growth Factor Receptor Endocrinology, November 1, 2005; 146(11): 4609 - 4618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bjorndahl, R. Cao, L. J. Nissen, S. Clasper, L. A. Johnson, Y. Xue, Z. Zhou, D. Jackson, A. Jon Hansen, and Y. Cao Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo PNAS, October 25, 2005; 102(43): 15593 - 15598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Platek, V. Krogh, A. Micheli, R. Browne, E. Meneghini, S. Sieri, H. J. Schunemann, V. Pala, M. Barba, G. E. Wilding, et al. Serum Fructosamine and Subsequent Breast Cancer Risk: A Nested Case-Control Study in the ORDET Prospective Cohort Study Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 271 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Burtrum, Z. Zhu, D. Lu, D. M. Anderson, M. Prewett, D. S. Pereira, R. Bassi, R. Abdullah, A. T. Hooper, H. Koo, et al. A Fully Human Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Blocks Ligand-Dependent Signaling and Inhibits Human Tumor Growth in Vivo Cancer Res., December 15, 2003; 63(24): 8912 - 8921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Stoeltzing, W. Liu, N. Reinmuth, F. Fan, A. A. Parikh, C. D. Bucana, D. B. Evans, G. L. Semenza, and L. M. Ellis Regulation of Hypoxia-Inducible Factor-1{alpha}, Vascular Endothelial Growth Factor, and Angiogenesis by an Insulin-Like Growth Factor-I Receptor Autocrine Loop in Human Pancreatic Cancer Am. J. Pathol., September 1, 2003; 163(3): 1001 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Maloney, J. L. McLaughlin, N. E. Dagdigian, L. M. Garrett, K. M. Connors, X.-M. Zhou, W. A. Blattler, T. Chittenden, and R. Singh An Anti-Insulin-like Growth Factor I Receptor Antibody That Is a Potent Inhibitor of Cancer Cell Proliferation Cancer Res., August 15, 2003; 63(16): 5073 - 5083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Lee, R. Schiff, X. Cui, D. Sachdev, D. Yee, A. P. Gilmore, C. H. Streuli, S. Oesterreich, and D. L. Hadsell New Mechanisms of Signal Transduction Inhibitor Action: Receptor Tyrosine Kinase Down-Regulation and Blockade of Signal Transactivation Clin. Cancer Res., January 1, 2003; 9(1): 516S - 523S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Standal, M. Borset, S. Lenhoff, F. Wisloff, B. Stordal, A. Sundan, A. Waage, and C. Seidel Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor Blood, December 1, 2002; 100(12): 3925 - 3929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Muti, T. Quattrin, B. J. B. Grant, V. Krogh, A. Micheli, H. J. Schunemann, M. Ram, J. L. Freudenheim, S. Sieri, M. Trevisan, et al. Fasting Glucose Is a Risk Factor For Breast Cancer: A Prospective Study Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1361 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C L Chernicky, H Tan, L Yi, J R L. de Mola, and J Ilan Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo Mol. Pathol., April 1, 2002; 55(2): 102 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Stephen, L. E. Shaw, C. Larsen, D. Corcoran, and P. D. Darbre Insulin-like Growth Factor Receptor Levels Are Regulated by Cell Density and by Long Term Estrogen Deprivation in MCF7 Human Breast Cancer Cells J. Biol. Chem., October 19, 2001; 276(43): 40080 - 40086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Melmed CLINICAL PERSPECTIVE: Acromegaly and Cancer: Not a Problem? J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2929 - 2934. [Full Text] [PDF]
|
|
|
|
|
|
G. von Wichert, P. M. Jehle, A. Hoeflich, S. Koschnick, H. Dralle, E. Wolf, B. Wiedenmann, B. O. Boehm, G. Adler, and T. Seufferlein Insulin-like Growth Factor-I Is an Autocrine Regulator of Chromogranin A Secretion and Growth in Human Neuroendocrine Tumor Cells Cancer Res., August 1, 2000; 60(16): 4573 - 4581. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. B. Hazan, G. R. Phillips, R. F. Qiao, L. Norton, and S. A. Aaronson Exogenous Expression of N-Cadherin in Breast Cancer Cells Induces Cell Migration, Invasion, and Metastasis J. Cell Biol., February 21, 2000; 148(4): 779 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Pandini, R. Vigneri, A. Costantino, F. Frasca, A. Ippolito, Y. Fujita-Yamaguchi, K. Siddle, I. D. Goldfine, and A. Belfiore Insulin and Insulin-like Growth Factor-I (IGF-I) Receptor Overexpression in Breast Cancers Leads to Insulin/IGF-I Hybrid Receptor Overexpression: Evidence for a Second Mechanism of IGF-I Signaling Clin. Cancer Res., July 1, 1999; 5(7): 1935 - 1944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Jackson, M. F. White, and D. Yee Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer Cells J. Biol. Chem., April 17, 1998; 273(16): 9994 - 10003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. Silberstein, K. Van Horn, P. Strickland, C. T. Roberts Jr., and C. W. Daniel Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer PNAS, July 22, 1997; 94(15): 8132 - 8137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Urban and Y. Bodenburg Transcriptional Activation of the Porcine P450 11A Insulin-like Growth Factor Response Element in MCF-7 Breast Cancer Cells J. Biol. Chem., December 6, 1996; 271(49): 31695 - 31698. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
